Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They wont listen
That was the most pathetic video/promotion/PR i have ever seen. The dude didnt even know who he was talking to or remember where he was at.
GLTA. LMAO
Why is the float so wide.
Bid 0057/ask 0066
Last 0063
ABcann Goes from RTO to $43 Million in Cash in 3 Months -- CFN Media
8/3/17, 6:00 AM
SEATTLE, WA -- (Marketwired) -- 08/03/17 -- CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing ABcann Global Corporation's (TSX VENTURE: ABCN) (OTCQB: ABCCF) tremendous progress from its reverse takeover transaction in May to having $43 million in cash now (with a market cap of about $90 million), and where the company is headed over the coming quarters.
High Quality Product
ABcann has spent considerable resources on developing consistent pharmaceutical-grade products that are organically grown without pesticides. This avoids many of the recall issues that other licensed producers have experienced involving the use of banned pesticides. At the same time, the company's $1.5 million, three-year investment in research and development has helped it double industry average yields to cultivate products at a very low cost per gram.
In a recent conversation ABcann CEO Aaron Keay said, "We have spent years mastering our proprietary growing techniques to avoid the use of pesticides. This has led to a repeatable, standardized product the public can trust. Not only that, as our reputation grows in the patients' eyes the word has spread to where we will be expanding our business -- globally. Our dedication to provide a pesticide free, organic, standardized product has resulted in inquiries from industry leaders, competitors, celebrities, and governments."
The high yields of pesticide free, standardized product are especially important when comparing various licensed producers. Production capacity is of course an important metric, and ABcann's proprietary growing methods mean that the company can get much more product out of much less space. Additionally, sizable recalls due to pesticides have impacted several producers' bottom lines, but ABcann removes that possibility by using no pesticides at all.
Rapid Expansion Strategy
ABcann is investing the cash on its balance sheet into an ambitious expansion strategy, which should limit shareholder dilution and accelerate its growth rates. With its proprietary growing technique, the company is in a great position to deploy capital and production knowledge on a massive scale, while competing on both price and quality.
On July 26, the company confirmed that plans to commence construction at its Kimmett facility in the third quarter remain on track and the previously announced plans for a 71,000 sq. ft. Phase I plan have been expanded to 100,000 sq. ft. The company also announced an immediately expansion and construction effort at its production facility in Vanluven to double production capacity and serve its growing patient base on an expedited timeline.
The company believes that its $43 million cash position will be sufficient to complete both the Phase I 100,000 sq. ft. Kimmett facility and the expansion at Vanluven. The Vanluven expansion should begin producing results in Q1'18, while the Kimmett facility should come online by Q4'18. The near-term revenue from these expansion efforts should be sufficient for financing future expansion efforts as recreational legalization goes into effect next year.
Please follow the link to see the interview and read the full article: http://www.cannabisfn.com/abcann-goes-rto-43-million-cash-3-months/
Learn how to become a CFN Media featured company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/
Download the CFN Media iOS mobile app to access the world of cannabis from your smart phone: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
Disclaimer:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.
CFN Media
Frank Lane
206-369-7050
flane@cannabisfn.com
Source: CFN Media
Nice close today. % is moving. Hop in now!!!
Wealth Daily
Time to Invest in ABcann Global (TSX-V: ABCN)
Written By: Jeff Siegel
Posted: May 31, 2017
Sign Up
Some said it would be the biggest legal cannabis IPO of the year.
It wasn’t.
ABcann Global (TSX-V: ABCN) debuted at $1.50
Today it trades for about a buck
But don’t get too preoccupied with the company’s debut on the TSX Venture. It’s somewhat irrelevant.
While the timing wasn’t particularly perfect, as cannabis stocks were actually selling off when ABcann went public, the company is one of the strongest in the space. It’s actually a bit undervalued at the moment.
In fact, the good folks over at Cannabis Wheaton recently announced they will subscribe for $15 million of ABcann common shares at a valuation of $2.25 per share. That’s one heck of a premium to the current market price, which tells me that ABcann may have a lot more value than the market is giving it credit for.
If you’re unfamiliar with ABcann, here’s what I wrote about the company before it went public ...
ABcann currently has a fully-operational 14,500 sq. ft. facility with a production capacity of 1,000 kg. It’s also in the process of developing a 150,000 sq. ft. facility with a production target capacity of 40,000 kg per year.
In addition to its Canadian operations, it’s also aggressively moving into the European, Australian and Israeli markets. The latter, by the way, could end up being one that really sets ABcann apart from other Canadian producers. And this is all thanks to a company called Syqe Medical
Syqe Medical
Syqe Medical is an Israeli tech firm that’s developed the world’s first selective-dose pharmaceutical grade cannabis inhaler.
For doctors prescribing cannabis, this is the holy grail as it allows for a level of dosing precision that’s never been seen before. The inhaler uses 100 microgram dosing precision, real-time thermal and flow controllers, lung interfacing and wireless connectivity. This is beyond next-generation stuff, folks. And I’m all over it. So is ABcann.
You see, ABcann has already successfully shipped product to Syqe in Israel and the company is heavily involved in ongoing testing and R&D.
Apparently, the founder of Syqe, Perry Davidson loves ABcann, saying, “After visiting Abcann’s production facility in Canada, I personally witnessed that their production technologies put them in a class with the best in the world in their ability to produce standardized pharmaceutical grade cannabis.”
This is good company to be in.
It should also be noted that Syqe’s inhaler is being marketed by Teva Pharmaceuticals, a major pharmaceutical player with FY 2016 net revenues of $21.9 billion.
But getting back to the basics, ABcann is licensed, operational cultivator in Canada that grows pesticide-free cannabis (a superior niche), and has experienced a YTD customer growth rate of 30% month over month.
The company’s high yields offer a low cost-per-gram product, and its customer retention rate is 94.7 percent, which is very impressive.
The bottom line is that ABcann is a serious player in the legal cannabis space, and at current levels, it’s significantly undervalued.
Sign Up
Ditto that !
IMO
IT WILL TAKE OFF
Once we get over dollars!!!
N submit. It may happen but not soon!! Lol
Finally on OTCQB. Lets get this party started!!
http://mailchi.mp/dc7c69d935ba/abcann-global-announces-listing-on-the-otcqb-marketplace-and-the-frankfurt-stock-exchange?e=018fd92cc7
So... we all holding??
Agree. Im in long also
Here is a great Q/A from the CEO from last week. Hope this helps
https://www.reddit.com/r/weedstocks/comments/6e8bmo/this_is_aaron_keay_ceo_of_abcann_global_ill_be/
Company holders??
Your guess is as good as mine.
Dont think so. It bottomed out at .62 and has a consistent up rising from there. Imo dont think you will see <.72 I bought in a lil early at .85 n im ok with that. With this news i posted i feel it will hit .85-.90 this week or so
Its starting to move.
It will hit 2.25 Canadian real soon and then some.
Then when it goes OTC it will explode^^^^ imo
Ive been talkin bout this for 3 wks
This is great news.
Yes sir!!! Lets get this goin!!
Sure what you're looking for here
Thru Ameritrade its ABCCF.
Its still thru TSXV.
ABCann will be coming out soon on OTC
Im trading now thru AMERITRADE
You have to deviate the Can $ from US $. Its moving up. See my post today
Oops. ABCCF
ABCann # ABCNNF
Home
News
Policy
Featured Companies
Thought Leaders
Conferences
Industry Reports
Contact
Become A Featured Company
ABcann: A Compelling Value After Going Public
inShare
Ryan Allway
May 16th, 2017
Feature Stories, News
Canada’s cannabis industry could be worth upwards of $22.6 billion over the coming years, while many analysts are predicting a shortfall in supply. As a result, licensed producers have become an attractive investment opportunity, with many approaching C$1 billion valuations over the past several quarters. Investors may want to take a look beyond the headline licensed producers toward newer entrants to the market that have only recently gone public.
In this article, we will take a look at ABcann Global Corp. (TSXV: ABCN) (OTC: ABCCF) following its going-public transaction and why investors may want to consider investing.
Attractive Comparable Valuation
There are about 40 licensed producers that have received approval from Health Canada to cultivate and sell medical cannabis to consumers. The largest company in the space is Canopy Growth Corp. (TSX: WEED), which has become the first cannabis ‘unicorn’ with a valuation that’s well over C$1 billion. Many other licensed producers are close to achieving these kinds of valuations as they ramp up production and revenue.
Company Name Ticker Symbol Market Capitalization
Canopy Growth Corp. TSX: WEED C$1.37 Billion
Aurora Cannabis Inc. CA: ACB C$844.48 Million
Aphria Inc. CA: APH C$815.19 Million
Organigram Holdings Inc. CA: OGI C$258.55 Million
Supreme Pharmaceuticals Inc. CNX: SL C$243.74 Million
* Data as of May 10, 2017.
ABcann Global is attractively priced by comparison with a market capitalization of about C$85 million, despite being one of the first licensed producers approved by Health Canada in 2014. The company hasn’t scaled up its production as quickly as other LPs, but it has signed high-profile partnerships with companies like Syqe Medical Inc. – the innovator behind the first metered dosage inhaler – and developed some of the highest yields in the industry.
In addition, the company has the cash on hand to significantly expand its capacity over the near-term. Management anticipates that its Van Luven facility will double its capacity, to about 29.000 square feet, this year while the Kimmet facility will come online next year with a 150,000 square foot presence.
Experienced Management Team
ABcann Global has an experienced management team that’s well-positioned to execute on plans to become a leader in the space.
Chairman Ken Clement has developed a strong rapport with Health Canada and cultivated several strategic partnerships around the world. His goal of standardizing production and doses of cannabinoids has help shaped the company’s unique focus relative to other licensed producers that are focused on simply maximizing production of commoditized products that will eventually be hard to compete against as the market grows.
CEO Aaron Keay has over 10 years of experience across many different sectors, serving in corporate finance, senior management, and board member roles. With a history of raising over $250 million, Mr. Keay is well-positioned to help the company secure funding and grow. Mr. Keay is also joined by a seasoned executive management team with experience across areas of management, finance, and the operation of cannabis businesses.
Finally, the company has developed a solid board of advisors that includes the ‘father of cannabis’, Dr. Raphael Mechoulam, Ph.D. Dr. Mechoulam is an organic chemist and professor of Medicinal Chemistry at the Hebrew University of Jerusalem. He’s best known for being the first scientist to isolate tetrahydrocannabinol (THC) and then cannabidiol (CBD) in 1963. Dr. Mechoulam is joined by many other prominent researchers and scientists in the field.
Rapidly Growing Market
Canada’s cannabis industry could be worth between $12.7 billion and $22.6 billion by 2020, according to Deloitte Canada, eclipsing the combined sales of beer, wine, and spirits. The country is widely expected to implement recreational legalization by early next year, which could open the market significantly beyond the medical users that are currently served under the Access to Cannabis for Medical Purposes Regulations – or ACMPR.
PI Financial believes that there could be a shortfall in supply with only about 40 companies licensed by Health Canada to grow and sell the drug. According to a recent report, the analyst reckons that LPs would need to cultivate a total of 610,000 kilograms to fulfill domestic and export demand by 2019. The problem is that existing capacity would fall short and lead to a 200,000 kilogram shortfall and it could be difficult to onboard enough new LPs.
“The rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall in supply in a legalized market in the short-term until production capacities catch up by 2020,” said Canaccord Genuity Group analysts in a November 2016 research note. This could create an enormous opportunity for existing licensed producers that enjoy an oligopoly of sorts.
Looking Ahead
ABcann Global Corp. (TSXV: ABCN) (OTC: ABCCF) represents a compelling investment opportunity in Canada’s burgeoning cannabis industry. With a focus on standardization and dosing, the company is developing a competitive edge in the medicinal side of the industry while building out its production capacity and its high-yield strategies. Investors may want to keep an eye on the stock following its going-public transaction on May 4.
For more information, visit the company’s corporate website at www.abcannglobal.com.
Ryan Allway
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist.
Search CannabisFN
Press Coverage
Marijuana Index
Marijuana Index Global 464.27 0.12
Today 5d 1m 3m 1y
Visit the Marijuana Index
Discover Cannabis Investments
Sign-up for our free cannabis investment newsletter to discover the latest opportunities in the space.
Name
E-Mail Address
Visit the CFN Video Library
Join Our Facebook Page
Top Videos
Daniel Yazbeck of MyDx Inc.
Daniel Yazbeck of MyDx Inc.
In this interview, CFN’s Mike Elliott speaks with MyDx Inc. CEO Daniel Yazbek about the company’s affordable portable analyzer that provides real-time chemical analyses and fits in the palm of the hand. MyDx Inc. (OTCQB: MYDX) is a science and technology company based in San Diego, California, whose mission is to help people Trust & Verify™ […]
Leslie Bocskor of Electrum Partners
Leslie Bocskor of Electrum Partners
In this recent video with Leslie Bocskor, Founder of Electrum Partners, Dan Wise explores what’s been happening at Electrum Partners over the last year. The interview focuses on the wealth of experience Electrum Partners provides in business services, strategic advice, and license procurement in the cannabis industry.
Invictus MD Strategies Corp.
Invictus MD Strategies Corp.
Invictus MD targets companies with proven brands, strong customer focus, and significant growth potential.
One World Cannabis, Ltd.
One World Cannabis, Ltd.
One World Cannabis Ltd. is an Israeli-based company founded in 2014 by a group of professionals with expertise in the field of medical cannabis treatment and medical cannabis regulatory affairs. The company’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions.
Network Partners
Hemp Business Journal
CWCB Expo
Viridian
Fresh Toast
TNM News
Follow Us on Social Media
Facebook
LinkedIn
Twitter
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Learn How Your Company can Be Covered on CFN Media
Learn More About the CFN Media Sponsored Content Program
Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.
Copyright © TDM Financial LLC · All Rights Reserved · Privacy Policy · Legal Disclaimer
.66 USA Now
ABcann Medicinals (TSXV: ABCN) Has Strong Start with Canadian TSX Venture Exchange Listing
Envoyer par e-mail
05/08/2017 | 09:05 pm
Going public appears to be paying off for ABcann Medicals (TSXV: ABCN), since the medical cannabis grower launched its initial public offering (IPO) on the TSX Venture Exchange. Although the IPO was just launched on May 4 (http://nnw.fm/Lt5DO), its value took off, soaring over 26% on the first day and trading over 25% of the total volume on the exchange. ABcann is one of Canada’s major legal cannabis producers, and the public offers are set to provide even more investor benefits as the recreational marijuana market is now positioned for nationwide legalization.
Raising capital was part of the company’s decision to launch a public offering. ABcann Medicinals was recently acquired by ABcann Global Corporation, which included capital raises of $26.8 million to be used to expand production. In connection with the acquisition, W. Brett Wilson, a financing expert specializing in building early stage ventures, was appointed to the Advisory Board.
The IPO launch has great potential for the company, and much profit is anticipated. Canadian cannabis IPOs have seen share prices rise 700% to 1,400%, but, unlike other medical marijuana companies in the country, ABcann has substantial medical marijuana growing experience and access to technology. Its cultivation and yield has enabled it to become one of the most dominant Canadian firms of its kind. It was one of the first to obtain a license to produce from Canada, which involves a 6-step program and extensive background check. Companies must also invest in their operations, and build their facilities, before being granted a license, which happens with only 3% of those who apply.
ABcann compares favorably with other companies in the industry. Supreme, as an example, has a market cap of $250m and doesn’t have a sales license. Hydropothecary, at $150m, just got its sales license suspended. Emblem, which has the same size facility as ABcann, is valued at $200m. Clearly, ABcann’s current market cap is low, yielding obvious opportunities for investors.
As of now, ABcann is licensed to sell to the entire Canadian market. It can also form partnerships to sell to the U.S. market, and there are plans for Europe and Australia. The company’s computer-controlled environmental system maximizes not only productivity and yield, but also the quality of its products. A collaboration with the Controlled Environmental Systems Research Facility, begun in 2014, helped it identify the best lighting, air quality, and temperature for growing marijuana. The partnership has also helped the company understand the ideal plant nutrition to perfect the finished product.
ABcann’s yield per square foot ranges from 250 to 300 grams, compared to the industry average of 60 grams per square foot. Less water, energy, and fertilizers are used during the process, which also does not require pesticides. So, as the company’s production process has improved, so have opportunities for investors as its IPO continues to spur rising valuations.
For more information about ABcann and its recently launched IPO on the TSX Venture Exchange, visit www.abcann.ca
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Copyright © 2015 - 2017 (NetworkNewsWire 1324 Lexington Ave., Suite 417 New York, NY 10128), source NetworkNewsWire
Great news here..
ABcann Extends Agreement With Medical Cannabis Pioneer
May 9th, 2017 – Ottawa, ON – ABcann Global Corporation (ABCN.V) (the “Company”) is pleased to announce that Raphael Mechoulam has agreed to extend his role as an advisor to the Company.
Mechoulam is an Israeli Organic Chemist, and a professor at the Hebrew University of Jerusalem’s Medical Faculty, Institute for Drug Research. Professor Mechoulam has been nominated for the Nobel Prize, and is often regarded as the "Father of Marijuana Research."
Professor Mechoulam has been a pioneer in medicinal cannabis research for more than five decades. His most significant cannabis research accomplishments include determining the chemical structure of cannabidiol (CBD) in 1963 which led to isolating and synthesizing tetrahydrocannabinol (THC) in 1964 and isolating and elucidating the structure of the brain's first endogenous cannabinoid, Anandamide, in 1992.
“Professor Mechoulam’s experience in medicinal cannabis is an invaluable resource for ABcann as we enter the most aggressive growth stage in the company’s history. The Company has invested heavily to build and extend its early leadership in advanced pharmaceutical-grade cannabis production. Professor Mechoulam’s advice, guidance, and unmatched expertise in the field has played a major role in achieving this, says Aaron Keay CEO and Director of ABcann.
“I have followed the development of cannabis for medical use for many years. There is no doubt that it is very helpful in numerous diseases, however many physicians refrain from prescribing it. I believe that the route followed by ABcann for standardized cannabis grown under strict conditions, leading to reproducible contents, will not only satisfy physicians but will also make possible clinical trials which will develop the evidence to transform how cannabis is perceived by the pharmaceutical industry and the regulatory agencies” said Professor Mechoulam.
“The Professor’s agreement to extend his relationship with ABcann is one of the strongest votes of confidence our company could ever receive,” says Ken Clement, Founder and Executive Chairman of ABcann.
Please click on the link to view our corporate presentation.
Read our Corporate Presentation
ON BEHALF OF THE BOARD OF DIRECTORS OF ABCANN GLOBAL CORPORATION
“Aaron Keay”
Aaron Keay
CEO and Director